Palop JJ, Mucke L. Amyloid-β–induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rudelli RD, Ambler MW, Wisniewski HM. Morphology and distribution of Alzheimer neuritic (senile) and amyloid plaques in striatum and diencephalon. Acta Neuropathol. 1984;64:273–81.

Article  CAS  PubMed  Google Scholar 

Attems J, Thal DR, Jellinger KA. The relationship between subcortical tau pathology and Alzheimer’s disease. Biochem Soc Trans. 2012;40:711–5.

Article  CAS  PubMed  Google Scholar 

Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B, et al. Ascending monoaminergic systems alterations in Alzheimer’s disease. Translating basic science into clinical care. Neurosci Biobehav Rev. 2013;37:1363–79.

Article  CAS  PubMed  Google Scholar 

Lopez OL, Wisnieski SR, Becker JT, Boiler F, DeKosky ST. Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol. 1997;54:969–75.

Article  CAS  PubMed  Google Scholar 

Rinne JO, Säkö E, Paljärvi L, Mölsä PK, Rinne UK. Brain dopamine D-2 receptors in senile dementia. J Neural Transm. 1986;65:51–62.

Article  CAS  PubMed  Google Scholar 

Joyce JN, Smutzer G, Whitty CJ, Myers A, Bannon MJ. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson’s, Alzheimer’s with parkinsonism, and Alzheimer’s disease. Mov Disord. 1997;12:885–97.

Article  CAS  PubMed  Google Scholar 

Gibb WR, Mountjoy CQ, Mann DM, Lees AJ. The substantia nigra and ventral tegmental area in Alzheimer’s disease and Down’s syndrome. J Neurol Neurosurg Psychiatry. 1989;52:193–200.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kemppainen N, Laine M, Laakso MP, Kaasinen V, Någren K, Vahlberg T, et al. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer’s disease. Eur J Neurosci. 2003;18:149–54.

Article  CAS  PubMed  Google Scholar 

Cortés R, Probst A, Palacios J. Decreased densities of dopamine D1 receptors in the putamen and hippocampus in senile dementia of the Alzheimer type. Brain Res. 1988;475:164–7.

Article  PubMed  Google Scholar 

Pievani M, Bocchetta M, Boccardi M, Cavedo E, Bonetti M, Thompson PM, et al. Striatal morphology in early-onset and late-onset Alzheimer’s disease: a preliminary study. Neurobiol Aging. 2013;34:1728–39.

Article  CAS  PubMed  Google Scholar 

Sala A, Caminiti SP, Presotto L, Pilotto A, Liguori C, Chiaravalloti A, et al. In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phases. Alzheimers Res Ther. 2021;13:1–12.

Article  Google Scholar 

Pizzolato G, Chierichetti F, Fabbri M, Cagnin A, Dam M, Ferlin G, et al. Reduced striatal dopamine receptors in Alzheimer’s disease: Single photon emission tomography study with the D sub 2 tracer [sup 123 I]-IBZM. Neurology. 1996;47:1065–8.

Article  CAS  PubMed  Google Scholar 

Koch G, Di Lorenzo F, Bonnì S, Giacobbe V, Bozzali M, Caltagirone C, et al. Dopaminergic modulation of cortical plasticity in Alzheimer’s disease patients. Neuropsychopharmacology. 2014;39:2654–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koch G, Motta C, Bonnì S, Pellicciari MC, Picazio S, Casula EP, et al. Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial. JAMA Netw Open. 2020;3:e2010372–e2010372.

Article  PubMed  PubMed Central  Google Scholar 

Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14:535–62.

Article  Google Scholar 

Boccardi M, Altomare D, Ferrari C, Festari C, Guerra UP, Paghera B, et al. Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET with [18F]-florbetapir (INDIA-FBP) study. JAMA Neurol. 2016;73:1417–24.

Article  PubMed  Google Scholar 

Pilotto A, Schiano di Cola F, Premi E, Grasso R, Turrone R, Gipponi S, et al. Extrastriatal dopaminergic and serotonergic pathways in Parkinson’s disease and in dementia with Lewy bodies: a 123 I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. 2019;46:1642–51.

Article  CAS  PubMed  Google Scholar 

Caminiti SP, Pilotto A, Premi E, Galli A, Ferrari E, Gipponi S, et al. Dopaminergic connectivity reconfiguration in the dementia with Lewy bodies continuum. Parkinsonism Relat Disord. 2023;108:105288.

Article  CAS  PubMed  Google Scholar 

Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885–912.

Article  PubMed  PubMed Central  Google Scholar 

Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu ÖL, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123 I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443–50.

Article  CAS  PubMed  Google Scholar 

Iaccarino L, Sala A, Caminiti SP, Presotto L, Perani D, Initiative ADN. In vivo MRI structural and PET metabolic connectivity study of dopamine pathways in Alzheimer’s disease. J Alzheimer’s Dis. 2020;75:1003–16.

Article  Google Scholar 

Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89.

Article  CAS  PubMed  Google Scholar 

Shigekiyo T, Arawaka S. Laterality of specific binding ratios on DAT-SPECT for differential diagnosis of degenerative parkinsonian syndromes. Sci Rep. 2020;10:15761.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia. 2011;7:263–9.

Article  PubMed  Google Scholar 

Nobili A, Latagliata EC, Viscomi MT, Cavallucci V, Cutuli D, Giacovazzo G, et al. Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer’s disease. Nat Commun. 2017;8:14727.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreno-Castilla P, Rodriguez-Duran LF, Guzman-Ramos K, Barcenas-Femat A, Escobar ML, Bermudez-Rattoni F. Dopaminergic neurotransmission dysfunction induced by amyloid-β transforms cortical long-term potentiation into long-term depression and produces memory impairment. Neurobiol Aging. 2016;41:187–99.

Article  CAS  PubMed  Google Scholar 

Frings L, Hellwig S, Spehl TS, Bormann T, Buchert R, Vach W, et al. Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer’s disease. Brain. 2015;138:3089–99.

Article  PubMed  Google Scholar 

Pilotto A, Bongianni M, Tirloni C, Galli A, Padovani A, Zanusso G. CSF alpha‐synuclein aggregates by seed amplification and clinical presentation of AD. Alzheimer’s Dement. 2023;19:3754–9.

Article  CAS  Google Scholar 

Nyberg L, Karalija N, Salami A, Andersson M, Wåhlin A, Kaboovand N, et al. Dopamine D2 receptor availability is linked to hippocampal–caudate functional connectivity and episodic memory. Proc Natl Acad Sci. 2016;113:7918–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compen